Aurinia Pharmaceuticals (AUPH) Fair Value: +60.8% Upside
Aurinia Pharmaceuticals Inc Fair Value Analysis
Aurinia Pharmaceuticals Inc (AUPH) is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet needs. Its flagship product, LUPKYNIS (voclosporin), was the first FDA-approved oral treatment for active lupus nephritis in adults when launched in 2021. The company is also advancing aritinercept, a dual BAFF/APRIL inhibitor, in its pipeline. At a recent price of USD 15.98, our fair value estimate stands at USD 25.69, implying +60.8% upside and a Quality Score of 77/100, marking the stock as undervalued on our comprehensive framework.
Company Overview and Business Model
Aurinia focuses on commercializing innovative treatments in the autoimmune space. LUPKYNIS has established a growing revenue base through prescriptions for lupus nephritis patients. The company’s strategy centers on expanding adoption of this therapy while progressing next-generation assets like aritinercept to address broader autoimmune indications. This dual focus on near-term commercial execution and pipeline innovation underpins long-term growth prospects.
Why Aurinia Pharmaceuticals Appears Undervalued
Our fair value of USD 25.69 derives from 21 distinct valuation models that emphasize discounted cash flows, peer multiples, and scenario analysis tailored to biopharma dynamics. Analyst consensus targets hover around USD 17.25, reflecting a more conservative view. However, our models incorporate stronger assumptions around sustained LUPKYNIS uptake, potential label expansions, and successful advancement of aritinercept, leading to a higher intrinsic value assessment. The +60.8% gap highlights market underappreciation of the company’s recurring revenue potential and pipeline optionality.
Key valuation drivers include robust gross margins from LUPKYNIS, improving operating leverage as sales scale, and a clean balance sheet supporting R&D investment. Recent performance in 2025, including pipeline momentum that drove significant stock gains earlier, reinforces the bullish case. While broader biotech sentiment can pressure valuations, Aurinia’s commercial traction differentiates it from pure development-stage peers.
Key Risks to Consider
- Competition in the lupus nephritis market from emerging therapies could limit LUPKYNIS market share.
- Clinical or regulatory setbacks for aritinercept may delay or diminish pipeline value.
- Reimbursement pressures or pricing dynamics in specialty pharmaceuticals pose ongoing challenges.
- Volatility typical of small-cap biotechs may amplify short-term price swings regardless of fundamentals.
These risks are balanced against Aurinia’s established commercial asset and focused pipeline, which our models suggest provide a margin of safety at current levels.
Balanced Verdict on Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc presents a compelling opportunity for investors seeking exposure to autoimmune therapeutics. With our fair value significantly above market price and a solid Quality Score, the stock merits consideration within a diversified portfolio. Growth in LUPKYNIS adoption and pipeline progress could catalyze re-rating toward our estimated intrinsic value. For the latest personalized assessment, explore the free Fair Value Calculator to check Aurinia Pharmaceuticals Inc alongside 35,000+ other stocks using our 21-model approach and Quality Score framework. Always conduct thorough due diligence, as this is educational content and not financial advice.
Compare valuations across the sector using our fair value calculator for broader context on healthcare stocks.
Frequently Asked Questions
What is the fair value of Aurinia Pharmaceuticals Inc stock?
Our models estimate the fair value of Aurinia Pharmaceuticals Inc (AUPH) at USD 25.69, representing a +60.8% upside from the current price of USD 15.98.
Is Aurinia Pharmaceuticals undervalued?
Yes, based on our valuation framework incorporating 21 models and a Quality Score of 77/100, Aurinia Pharmaceuticals Inc is rated as undervalued with significant upside potential.
What drives Aurinia Pharmaceuticals valuation?
Key drivers include strong sales of LUPKYNIS for lupus nephritis, the promising aritinercept pipeline candidate, recurring revenue potential in autoimmune diseases, and robust profitability metrics supporting our higher fair value estimate.
Sources
Context gathered via live web search while writing this article:
- https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/valuation
- https://finance.yahoo.com/news/aurinia-pharmaceuticals-auph-pricing-reflect-220859896.html
- https://www.auriniapharma.com/investors
- https://public.com/stocks/auph/forecast-price-target
- https://www.webull.com/news/13936749634757632
- https://naga.com/en/instruments/AUPH.re
- https://tickernerd.com/stock/auph-forecast/
- https://valueinvesting.io/AUPH/valuation/fair-value
26 valuation models · 12,000+ stocks · evidence-based
Start free →